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PURPOSE.Mutations in the RS1 gene, which encodes retinoschisin, cause X-linked juvenile
retinoschisis, a retinal dystrophy in males. Retinoschisin specifically interacts with the
retinal sodium–potassium adenosine triphosphatase (Na/K-ATPase), a transmembrane
ion pump. Na/K-ATPases also bind cardiac glycosides, which control the activity of the
pump and have been linked to disturbances in retinal homeostasis. In this study, we
investigated the crosstalk between retinoschisin and cardiac glycosides at the retinal
Na/K-ATPase and the consequences of this interplay on retinal integrity.
METHODS. The effect of cardiac glycosides (ouabain and digoxin) on the binding of
retinoschisin to the retinal Na/K-ATPase was investigated via western blot and immunocy-
tochemistry. Also, the influence of retinoschisin on the binding of cardiac glycosides was
analyzed via enzymatic assays, which quantified cardiac glycoside-sensitive Na/K-ATPase
pump activity. Moreover, retinoschisin-dependent binding of tritium-labeled ouabain to
the Na/K-ATPase was determined. Finally, a reciprocal effect of retinoschisin and cardiac
glycosides on Na/K-ATPase localization and photoreceptor degeneration was addressed
using immunohistochemistry in retinoschisin-deficient murine retinal explants.
RESULTS. Cardiac glycosides displaced retinoschisin from the retinal Na/K-ATPase;
however, retinoschisin did not affect cardiac glycoside binding. Notably, cardiac glyco-
sides reduced the capacity of retinoschisin to regulate Na/K-ATPase localization and to
protect against photoreceptor degeneration.
CONCLUSIONS. Our findings reveal opposing effects of retinoschisin and cardiac glycosides
on retinal Na/K-ATPase binding and on retinal integrity, suggesting that a fine-tuned
interplay between both components is required to maintain retinal homeostasis. This
observation provides new insight into the mechanisms underlying the pathological effects
of cardiac glycoside treatment on retinal integrity.
Keywords: X-linked juvenile retinoschisis, retinoschisin, retina, Na/K-ATPase, cardiac
glycosides
Sodium–potassium adenosine triphosphatases (Na/K-ATPases) are plasma membrane-spanning ion pumps
that play a fundamental role in tissue homeostasis and devel-
opment (reviewed by Kaplan,1 Aperia et al.,2 and Krupin-
ski and Beitel3). Their minimal functional unit consists of
an α and a β subunit. Four different α isoforms (ATP1A1–
4) and three β isoforms (ATP1B1–3) are known in higher
eukaryotes, all of which are expressed in a tissue-specific
manner.4,5 In the retina, the Na/K-ATPases consist largely
of ATP1A3 (85%) and ATP1B2 (80%) subunits6 and conse-
quently are referred to as retinal Na/K-ATPases. Na/K-
ATPases are tightly regulated at various levels, such as
by cardiac glycosides, which halt its ion pump function
(reviewed by Therien and Blostein7). Serum-derived cardiac
glycosides can cross the blood–brain barrier and are highly
enriched in the retina,8–11 suggesting a role for endoge-
nous cardiac glycosides in retinal development and integrity.
Moreover, patients administered cardiac glycosides for the
treatment of chronic heart failure often experience a loss
of visual acuity as a negative side effect.11–14 Retinoschisin,
a protein secreted by photoreceptor and bipolar cells,15
binds to the retinal Na/K-ATPase.16,17 Mutations in the RS1
gene, which encodes retinoschisin, cause X-linked juvenile
retinoschisis (XLRS, OMIM #312700), a hereditary degenera-
tive disorder of the macula.18–20 Previous studies have shown
that retinoschisin is required for proper retinal Na/K-ATPase
localization and has a protective effect against photorecep-
tor degeneration.16,21–23
In this study, we investigated the interplay between
retinoschisin and cardiac glycoside binding at the retinal
Na/K-ATPase and its consequences on retinal integrity. We
chose to investigate the cardiac glycosides ouabain and
digoxin, which are endogenous hormones in humans24 but
are also widely used for the treatment of heart diseases.25
We show that these cardiac glycosides hamper retinoschisin
binding to the retinal Na/K-ATPase, whereas retinoschisin
does not affect cardiac glycoside affinity to the retinal Na/K-
ATPase. Notably, cardiac glycosides were found to impair
the capacity of retinoschisin to regulate Na/K-ATPase local-
ization and to protect against photoreceptor degeneration.
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MATERIALS AND METHODS
Animal Models
The study was conducted in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. Rs1h-knockout (retinoschisin-deficient) mice26
were kept on a C57BL/6 background for more than 20
generations. Mice were housed under specific pathogen-
free barrier conditions at the Central Animal Facility of the
University of Regensburg, in strict compliance with National
Institutes of Health guidelines. Mice were sacrificed 16 or
18 days after birth by cervical dislocation.
Cell Culture
Y-79 cells (ATCC; LGC Standards GmbH, Wesel, Germany)
and Hek293 cells (Hek293 EBNA cells; Invitrogen, Carlsbad,
CA, USA) were grown as described in Plössl et al.22
Media and Media Supplies
All media and cell culture supplies were purchased from Life
Technologies (Carlsbad, CA, USA).
Primary Antibodies
Primary antibodies against ATP1A3 and ATP1B2 (Thermo
Fisher Scientific, Waltham, MA, USA) and against ACTB
(Sigma Aldrich, St. Louis, MO, USA) were used according
to each manufacturer’s recommendations. Primary antibod-
ies against retinoschisin were kindly provided by Robert
Molday (University of British Columbia, Vancouver, Canada)
and diluted as described previously.21
Expression Constructs
The generation of expression constructs for non-tagged
and Myc-tagged retinoschisin (NM_000330.4) is described
in Plössl et al.23; for ATP1A3 (NM_152296.4) and ATP1B2
(NM_001678.4), in Friedrich et al.16; for bicistronic expres-
sion of ATP1A3 and ATP1B2, in Plössl et al.27; and for the
ouabain-insensitive ATP1A3 mutant, in Plössl et al.22
Transfection
Hek293 cells subjected to 3H-labeled ouabain assays or
to immunocytochemistry were transfected with Bio Mirus
TransIT-LTI Transfection Reagent (Thermo Fisher Scientific).
All other transfections were performed using the calcium-
phosphate method.28
Purification of Recombinant Retinoschisin
Purification of recombinant retinoschisin from the super-
natant of Hek293 cells, heterologously expressing Myc-
tagged retinoschisin, was performed as described by Plössl
and colleagues.21,23 The supernatant of Hek293 cells trans-
fected with pCDNA3.1 (Thermo Fisher Scientific) was
subjected to the same purification procedure, and eluates
served as control treatment.
Retinoschisin Binding to Hek293 and Y-79 Cells
Retinoschisin binding to Hek293 cells was assessed as
described, with supernatant of Hek293 cells stably secreting
recombinant retinoschisin as input.16,21–23,27 Ouabain and
digoxin (for concentrations, see Figs. 1 and 2) were added
to the input and incubated for 1 hour (western blot) or 2
hours (immunocytochemistry). Retinoschisin binding to Y-
79 cells was performed likewise, but with 4 × 106 cells in
2 mL input (for ouabain and digoxin concentrations,
see Figs. 1 and 2). Western blot and immunocytochemi-
cal analyses were performed as described previously.16,22,27
Fluorescence microscopy was performed with an Axioskop2
mot plus microscope (Carl Zeiss Meditec, Oberkochen,
Germany) at 40× magnification.
Analysis of Na/K-ATPase Activity in Murine
Retinal Membranes
The Na/K-ATPase-catalyzed release of free phosphate was
measured colorimetrically in retinal membranes of wild-
type and retinoschisin-deficient mice (postnatal day 16)
as a function of ouabain and digoxin (for concentrations,
see Fig. 3), as described in Plössl et al.22 The values obtained
at 10−3 M ouabain, representing unspecific (not Na/K-
ATPase-catalyzed) adenosine triphosphate (ATP) cleavage,29
were subtracted from all other values. Data were processed
by nonlinear regression (SigmaPlot 12.5; Systat Software,
San Jose, CA, USA).
Tritium-Labeled Ouabain Binding Assays
Hek293 cells cultivated in 12-well plates were transfected
with a bicistronic expression construct for ATP1A3 and
ATP1B2 or an empty pCEP4 vector (Thermo Fisher Scien-
tific). Forty-eight hours after transfection, the medium
was replaced with 300 μL Dulbecco’s modified Eagle’s
medium containing purified retinoschisin (for concentra-
tions, see Fig. 4) or an equal volume of control eluate,
followed by a 30-minute incubation at 37°C. Subsequently,
tritium (3H)-labeled ouabain, 250 μCi (Perkin Elmer, Rodgau,
Germany; for concentrations, see Fig. 4), was added followed
by a 1-hour incubation at 37°C. Cells were resuspended in 1
mL PBS, centrifuged, and washed twice with PBS. The pellet
was dissolved in 100 μL 5% SDS and transferred to scin-
tillation cups with 5 mL of scintillation cocktail (Rotiszint
eco plus; Carl Roth GmbH + Co. KG, Karlsruhe, Germany).
Bound radioactivity was measured in a scintillation counter
for 1 minute.
The same protocol was applied to Y-79 cells, with the
following modifications: 8.5 × 105 cells were seeded in
24-well plates coated with poly-L-lysine. After 24 hours,
the medium was replaced by 1 mL RPMI 1640 medium
(Thermo Fisher Scientific) and retinoschisin (for concentra-
tions, see Fig. 4).
Cultivation of Murine Retinal Explants
Retinae from retinoschisin-deficient mice at postnatal day 18
were dissected and cultivated on filters as described previ-
ously.27,30 They were cultured in medium containing either
purified retinoschisin (333 ng/mL) or control eluate with
cardiac glycosides (for concentrations, see Figs. 5 and 6),
and the medium was replaced after 48 hours. After 4 days,
explants were processed for analysis.
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FIGURE 1. Effect of cardiac glycosides on retinoschisin binding to
the retinal Na/K-ATPase. (A, B) Hek293 cells were transfected with
expression constructs for ATP1A3 and ATP1B2. After 48 hours,
they were subjected to recombinant retinoschisin for 1 hour in
the presence of 0 (control), 10−7, 10−5, 10−3, or 10−2 M ouabain
(A) or 0 (control), 10−8, 10−7, 10−6, or 10−5 M digoxin (B),
followed by intensive washing. Retinoschisin binding was evalu-
ated by western blot analyses with antibodies against retinoschisin.
ACTB staining served as loading control. Densitometric quantifica-
tion of retinoschisin binding was performed on immunoblots from
five (A, ouabain treatment) or seven (B, digoxin treatment) individ-
ual experiments. Signals were normalized against ACTB and cali-
brated against the control. Data represent the mean ± SD. Asterisks
represent statistically significant differences compared to control (*P
< 0.05; Kruskall–Wallis test followed by Dunn’s multiple comparison
test and Bonferroni correction). (C–E) Hek293 cells were transfected
with expression constructs for ATP1A3 and ATP1B2. After 48 hours,
they were subjected to recombinant retinoschisin for 2 hours in the
presence of 0 M (control) or 10−3 M ouabain (C) or in the pres-
ence of 0 M (control) or 10−6 M digoxin, respectively (see Supple-
mentary Fig. S1A), followed by intensive washing. Subsequently,
retinoschisin binding was analyzed via immunocytochemistry with
Immunohistochemical Analyses of Retinal
Explants
Cryosectioning and immunolabeling of retinal explants were
performed as described previously.16 Sections were coun-
terstained with 4′,6-diamidino-2-phenylindol (DAPI, 1:1000;
Molecular Probes, Leiden, The Netherlands). TUNEL stain-
ing of retinal explants was performed using the In Situ
Cell Death Detection Kit, Fluorescein (Roche-11684795910,
provided by Sigma Aldrich), according to the manufacturer’s
instructions. Confocal microscopic images were taken with a
TCS SP5 confocal microscope (Leica Microsystems, Wetzlar,
Germany), at 40× magnification.
Statistical Analyses
The normality of the data was assessed by the Shapiro–Wilk
normality test. Data not following a Gaussian distribution
were analyzed using the Mann–Whitney U test (two exper-
imental groups) or the Kruskall–Wallis test, with post ad
hoc Dunn’s multiple comparison test and Bonferroni correc-
tion (more than two experimental groups). Data following
a Gaussian distribution were analyzed using Student’s t-test
(two experimental groups) or ANOVA with Tukey’s multi-
ple comparison test (more than two experimental groups).
Statistical analyses were performed using the XLSTAT add-in
software (Addinsoft Inc., New York, NY, USA).
RESULTS
Cardiac Glycosides Impair Retinoschisin Binding
to the Retinal Na/K-ATPase
First, the effect of cardiac glycosides on the binding of
retinoschisin to the retinal Na/K-ATPase was investigated. As
described previously,16,21–23 retinoschisin binds to Hek293
cells heterologously expressing the two subunits of the reti-
nal Na/K-ATPase (ATP1A3 and ATP1B2). We tested whether
exposure to ouabain (10−7, 10−5, 10−3, or 10−2 M) or digoxin
(10−8, 10−7 10−6, or 10−5 M) had an influence on the binding
capacity of retinoschisin.
Indeed, western blot analyses revealed that increasing
concentrations of ouabain (Fig. 1A) or digoxin (Fig. 1B)
impaired retinoschisin binding to Hek293 cells heterol-
ogously expressing ATP1A3 and ATP1B2. Interestingly,
antibodies against retinoschisin (red) and ATP1B2 (green). Scale
bars: 25 μm.Retinoschisin signals of 20 ATP1B2-expressing cells per
biological replicate were measured using ImageJ software (National
Institutes of Health, Bethesda, MD, USA). Data represent the mean
± SD of four (D, ouabain treatment) or five (E, digoxin treatment)
biological replicates, calibrated against the control. Asterisks show
statistically significant differences compared to control (*P < 0.05;
Mann–Whitney U test). (F–G) Y-79 cells were subjected to recombi-
nant retinoschisin for 1 hour in the presence of 0 (control), 10−6,
10−5, 10−4, 10−3, or 10−2 M ouabain (F) or 0 (control), 10−7, or 10−6
M digoxin (G), followed by intensive washing. Retinoschisin binding
was investigated by western blot analyses with antibodies against
retinoschisin. ACTB staining served as loading control. Densito-
metric quantification of retinoschisin binding was performed on
immunoblots from six (F, ouabain treatment) or four (G, digoxin
treatment) individual experiments. Signals were normalized against
ACTB and calibrated against the control. Data represent the mean ±
SD. Asterisks show statistically significant differences compared to
control (*P < 0.05; Kruskall–Wallis test followed by Dunn’s multiple
comparison test and Bonferroni correction).
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FIGURE 2. Effect of cardiac glycosides on ATP1B2 expres-
sion, retinoschisin levels in the supernatant containing recombi-
nant retinoschisin (input), and retinoschisin binding to ouabain-
insensitive Na/K-ATPases. (A, B) ATP1B2 levels in the Hek293 cells
used in retinoschisin binding experiments before (Figs. 1A, 1B)
were analyzed by western blot with antibodies against ATP1B2.
As described previously,22 anti-ATP1B2 staining revealed several
protein bands with molecular weights between 25 and 55 kDa,
reflecting differently N-glycosylated ATP1B2 subforms. Densito-
metric quantification of retinoschisin binding was performed on
immunoblots from five (A, ouabain treatment) or seven (B, digoxin
treatment) individual experiments. Signals were normalized against
digoxin showed a much stronger effect than ouabain (reduc-
tion to 33.0 ± 16.3% at 10−2 M ouabain and to 46.9 ± 21.0%
at 10−5 M digoxin; P < 0.05 compared to control).
Compared to the western blot analyses, the displace-
ment of retinoschisin by cardiac glycosides was even more
pronounced in the immunocytochemical analyses (Figs. 1C–
1E, Supplementary Fig. S1A), as 10−3 M ouabain or 10−6
M digoxin reduced retinoschisin binding to Hek293 cells
heterologously expressing the retinal Na/K-ATPase to 53.9
± 5.1% and 24.8 ± 19.1%, respectively, compared to control
(P < 0.05).
These results were corroborated in Y-79 cells, a human
retinoblastoma cell line that endogenously expresses the
retinal Na/K-ATPase.23 Y-79 cells exhibited a reduction in
retinoschisin binding, which was inversely proportional to
increasing cardiac glycoside concentrations (Figs. 1F, 1G).
Again, digoxin exerted a stronger effect than ouabain (41.3 ±
43.6% at 10−2 M ouabain and 42.4 ± 7.2% at 10−6 M digoxin;
P < 0.05 compared to control).
Next, we examined whether the inhibitory effect of
cardiac glycosides on retinoschisin binding is caused by
competition at the Na/K-ATPase or is the result of other
cellular processes. We used the transfected Hek293 cells
from the binding experiments described before (Figs. 1A,
1B) and quantified the expression level of ATP1B2, the
Na/K-ATPase subunit to which retinoschisin binds.22 Our
analyses revealed no effect of ouabain (Fig. 2A) or digoxin
(Fig. 2B) treatment on ATP1B2 levels. Furthermore, we
investigated whether cardiac glycosides affect retinoschisin
levels in the input. Hek293 cells heterologously express-
ing the retinal Na/K-ATPase were incubated with cardiac
glycosides (0, 10−3, or 10−2 M ouabain in Fig. 2C; 0,
ACTB and calibrated against the control. Data represent the mean ±
SD. (C–D) Hek293 cells were transfected with expression constructs
for ATP1A3 and ATP1B2. After 48 hours, they were subjected to
recombinant retinoschisin in the presence of 0 (control), 10−3, or
10−2 M ouabain (C) or 0 (control), 10−6, or 10−5 M digoxin (D).
After 1 hour and 2 hours, samples were taken from the supernatant
containing recombinant retinoschisin (input) and subjected to west-
ern blot analyses with antibodies against retinoschisin. Densito-
metric quantification of retinoschisin binding was performed on
immunoblots from six individual experiments. Signals were cali-
brated against the control. (E–F) Hek293 cells were transfected with
expression constructs for a ouabain-insensitive mutant of ATP1A3
(ATP1A3-OI) and ATP1B2. After 48 hours, they were subjected
to recombinant retinoschisin for 2 hours in the presence of 0
(control), 10−7, 10−5, 10−3, or 10−2 M ouabain (E) or in the pres-
ence of (control), 10−8, 10−7, 10−6, or 10−5 M digoxin (F), followed
by intensive washing. Retinoschisin binding was investigated by
western blot analyses with antibodies against retinoschisin. ACTB
staining served as loading control. Densitometric quantification of
retinoschisin binding was performed on immunoblots from each of
five individual experiments. Signals were normalized against ACTB
and calibrated against the control. Data represent the mean ± SD.
(G–I) Hek293 cells were transfected with expression constructs
for ATP1B2 and ATP1A3-OI. After 48 hours, they were subjected
to recombinant retinoschisin for 2 hours in the presence of 0 M
(control) or 10−3 M ouabain (G) or in the presence of 0 M (control)
or 10−6 M digoxin (see Supplementary Fig. S1B), followed by inten-
sive washing. Subsequently, retinoschisin binding was analyzed via
immunocytochemistry with antibodies against retinoschisin (red)
and ATP1B2 (green). Scale bars: 25 μm. Retinoschisin signals of
20 ATP1B2 expressing cells per biological replicate were measured
using ImageJ. Data represent the mean ± SD of four (H, ouabain
treatment) or five (I, digoxin treatment) biological replicates, cali-
brated against the control.
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FIGURE 3. Effect of retinoschisin on inhibition of Na/K-ATPase pump activity by cardiac glycosides. Na/K-ATPase catalyzed ATP hydrolysis
in murine retinal membrane fractions from (A, B) retinoschisin-deficient (open circles) and wild-type mice (closed circles) or from (C, D)
retinoschisin-deficient mice pre-incubated for 30 minutes with recombinant retinoschisin (1 μg/mL, closed circles) or control eluate (open
circles). Assays were performed in the presence of 0, 5 × 10−8, 10−7, 2.5 × 10−7, 5 × 10−7, 7.5 × 10−7, 10−6, 1.25 × 10−6, 1.5 × 10−6, 1.75
× 10−6, 2 × 10−6, 2.25 × 10−6, 2.5 × 10−6, 5 × 10−6, and 10−5 M ouabain (A, C) or in the presence of 0, 10−7, 5 × 10−7, 7.5 × 10−7, 10−6,
5 × 10−6, and 10−5 M digoxin (B, D). Data represent the mean ± SD of six (A, B) or five (C, D) biological replicates, calibrated against
values obtained for 0 M ouabain.
10−6, or 10−5, M digoxin in Fig. 2D) and retinoschisin,
as described before (Fig. 1). After incubation (1 hour for
western blot or 2 hours for immunocytochemical anal-
yses), retinoschisin levels in the input were unaffected
by the presence of the cardiac glycosides (Figs. 2C, 2D).
Finally, we investigated retinoschisin binding to Hek293
cells heterologously expressing ATP1B2 and a ouabain-
insensitive ATP1A3 (ATP1A3-OI) mutant. Due to two point
mutations at the ouabain binding site (Q108R and N119D),
ATP1A3-OI remains fully functional but can no longer bind
ouabain.22,31 It should also fail to bind digoxin, as crys-
tal structures exhibited similar interactions between the
steroid cores of ouabain and digoxin and the transmem-
brane helices of the α subunit.32 Hek293 cells heterolo-
gously expressing ATP1A3-OI and ATP1B2 were subjected
to the retinoschisin binding assays, applying the same treat-
ment conditions as before (Figs. 1A–1E). Neither ouabain nor
digoxin had an effect on the binding of retinoschisin to the
transfected Hek293 cells (Figs. 2E–2I, Supplementary Fig.
S1B), in contrast with the results obtained for Hek293 cells
transfected with normal ATP1A3 and ATP1B2 (Figs. 1A–1E).
Retinoschisin Does Not Affect Ouabain Binding
by the Retinal Na/K-ATPase
We next explored an influence of retinoschisin on cardiac
glycoside binding by investigating cardiac glycoside-induced
inhibition of the active ion transport of the Na/K-ATPase.
Thus, we performed the ouabain-sensitive ATP hydrolysis
assay22,29 to determine Na/K-ATPase activity in murine reti-
nal membranes. Increasing the concentrations of ouabain
(Figs. 3A, 3C) or digoxin (Figs. 3B, 3D) decreased the Na/K-
ATPase activity in all assays. However, the presence of
endogenous (Figs. 3A, 3B) or recombinant (Figs. 3C, 3D)
retinoschisin failed to affect the inhibitory capacity of
ouabain or digoxin (P > 0.05 compared with retinoschisin-
deficient retinae at all concentrations of ouabain or
digoxin).
In an alternative approach, we investigated the bind-
ing of 3H-labeled ouabain to Hek293 cells heterologously
expressing the retinal Na/K-ATPase in the presence of
retinoschisin. Our first assay assessed binding of ouabain
at different concentrations, in the presence of an excess
amount of retinoschisin determined in previous binding
assays (Supplementary Fig. S2A). With increasing concentra-
tions of 3H-labeled ouabain, bound radioactivity (measured
as counts per minute) increased (Fig. 4A). Compared to
control cells (transfected with pCEP4), Hek293 cells trans-
fected with a bicistronic expression vector for ATP1A3
and ATP1B2 showed an approximately twofold increase in
bound radioactivity, apparently reflecting additional ouabain
binding by the heterologously expressed retinal Na/K-
ATPase. However, retinoschisin had no effect on bound
radioactivity and thus on ouabain binding (Fig. 4A). We
performed additional analyses investigating the binding of
10−7 M ouabain in the presence of increasing amounts of
retinoschisin (Fig. 4B). Again, retinoschisin did not affect
ouabain binding to Hek293 cells heterologously expressing
the retinal Na/K-ATPase.
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FIGURE 4. Effect of retinoschisin on ouabain binding. (A, B) Hek293 cells were transfected with pCEP4 or with bicistronic expression
constructs for ATP1A3 and ATP1B2. (A) After 48 hours, cells were subjected to 1.5 μg/mL recombinant retinoschisin (RS1) or the same
volume of control eluate (ctr) for 30 minutes, followed by the addition of 0, 0.5 × 10−9, 10−8, 2.5 × 10−8, 5 × 10−8, or 10−7 M 3H-labeled
ouabain for 30 minutes. (B) Alternatively, cells were subjected to 0, 0.5, 1, 1.5, or 2 μg/mL RS1 or the same volume of control eluate (ctr)
for 30 minutes, followed by the addition of 10−7 M 3H-labeled ouabain for 30 minutes (#, without 3H-labeled ouabain). (C) Y-79 cells were
subjected to 120 ng/mL recombinant RS1 or the same volume of control eluate (ctr) for 30 minutes, followed by the addition of 0, 0.5 ×
10−9, 10−8, 2.5 × 10−8, 5 × 10−8, or 10−7 M 3H-labeled ouabain. (D) Alternatively, Y-79 cells were subjected to 0, 75, 150, 225, or 300 ng/mL
RS1 or the same volume of control eluate (ctr) for 30 minutes, followed by the addition of 10−7 M 3H-labeled ouabain and 30 minutes of
incubation (#, without 3H-labeled ouabain). (A–D) After incubation with retinoschisin and ouabain, cells were washed and lysed, and bound
radioactivity was determined in a scintillation counter. (A, C) Data represent the mean ± SD of measured counts/minute of five (A) or nine
(C) biological replicates. (B, D) Data represent the mean ± SD of five (B) or seven (D) biological replicates, calibrated against signals of
cells incubated with 3H-labeled ouabain but without retinoschisin or control eluate (gray bar).
Binding of 3H-labeled ouabain was also investigated in
Y-79 cells. In general, an excess amount of retinoschisin (as
determined in Supplementary Fig. S2B) had no effect on the
binding of 3H-labeled ouabain (in concentrations from 5 ×
10−9 to 10−7 M) by Y-79 cells (Fig. 4C). Furthermore, increas-
ing concentrations of retinoschisin did not affect binding of
10−7 M ouabain (Fig. 4D).
Cardiac Glycosides Hamper Regulation of Retinal
Na/K-ATPase Localization by Retinoschisin
Previous analyses have suggested that retinoschisin is
required for proper Na/K-ATPase localization in the
retina,16,21,22 as the presence of retinoschisin leads to a
pronounced enrichment of the retinal Na/K-ATPase at the
inner segments, compared to the outer nuclear layer, in
murine retinae. In contrast, retinoschisin deficiency results
in a diffuse distribution of the retinal Na/K-ATPase across
inner segments and the outer nuclear layer.16,21,22
We investigated the interplay of retinoschisin and
cardiac glycosides on retinal Na/K-ATPase localization in
retinoschisin-deficient retinal explants. Consistent with our
previous data, incubation of retinoschisin-deficient retinae
with retinoschisin led to Na/K-ATPase enrichment at the
inner segments (Fig. 5A). The ratio of Na/K-ATPase signal
intensity from the inner segments to the outer nuclear
layer, r(IS/ONL), was 2.76 ± 0.45 in retinoschisin-treated
explants compared with 1.57 ± 0.29 in control explants
(P < 0.01) (Figs. 5A, 5B). In explants treated with 10−5
M ouabain, the r(IS/ONL) was similar to that of control
explants (1.73 ± 0.56; P < 0.01 compared with retinoschisin-
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FIGURE 5. Effect of ouabain and retinoschisin on Na/K-ATPase localization. (A) Retinoschisin-deficient retinae explanted at postnatal day 18
were cultured for 4 days in medium containing retinoschisin (RS1) or the same volume of control eluate (ctr) in the presence of 0 or 10−5 M
ouabain (O) or in the presence of 0 or 10−6 M digoxin (D) (see Supplementary Fig. S3). After washing and embedding, cryosections of the
explants were subjected to staining with anti-Atp1a3-antibody (green), anti-retinoschisin antibody (red), and DAPI (blue, depicting nuclei).
Scale bar: 10 μm. (B, C) Na/K-ATPase signals in the inner segments and outer nuclear layer were measured using ImageJ. Data represent the
mean ± SD of five biological replicates for ouabain treatment (B) and of six biological replicates for digoxin treatment (C), calibrated against
the control. Asterisks represent statistically significant differences (*P < 0.05; ANOVA test followed by Tukey’s multiple comparison test). (D,
E) Retinoschisin signals in the inner segments were measured using ImageJ. Data represent the mean ± SD of five biological replicates for
ouabain treatment (D) and of six biological replicates for digoxin treatment (E), calibrated against the control. Asterisks represent statistically
significant differences (*P < 0.05; two-sided Student’s t-test).
treated explants), indicating that ouabain alone had no effect
on retinal Na/K-ATPase localization. When explants were
treated with retinoschisin and 10−5 M ouabain, the effect of
retinoschisin on retinal Na/K-ATPase enrichment was signif-
icantly reduced, with an r(IS/ONL) of 2.00 ± 0.47 (P <
0.05 compared with explants treated only with retinoschisin)
(Figs. 5A, 5B). Similar results were obtained with digoxin
(10−6 M) (Fig. 5C, Supplementary Fig. S3). In controls or
explants treated with digoxin or digoxin plus retinoschisin,
enrichment of the retinal Na/K-ATPase at the inner segments
was significantly reduced to r(IS/ONL) values of around
1.4, compared with explants treated only with retinoschisin,
which had an r(IS/ONL) of 2.64 ± 0.67 (P > 0.05).
Consistent with the previous results for Hek293 and Y-79
cells (Fig. 1), ouabain and digoxin treatment also decreased
retinoschisin binding to retinoschisin-deficient explants to
16.1 ± 15.4% or to 4.6 ± 3.5% (Figs. 5D, 5E), respec-
tively, compared with only retinoschisin-treated explants
(P < 0.01).
Antagonistic Effects of Cardiac Glycosides and
Retinoschisin on Retinal Integrity
Previous publications have reported that Rs1h-deficient
mice exhibit retinal degeneration, with a major burst
of apoptotic nuclei occurring in the outer nuclear layer,
around postnatal day 18.33,34 In our final assay, we
aimed to investigate how the interplay of cardiac glyco-
sides and retinoschisin affects retinal integrity. We there-
fore incubated Rs1h-deficient murine retinae explanted
at postnatal day 18, with recombinant retinoschisin or a
control eluate with or without cardiac glycosides (Fig. 6,
Supplementary Fig. S4).
After 4 days of incubation, retinoschisin-deficient retinal
explants incubated with retinoschisin showed fewer apop-
totic nuclei in the outer nuclear layer (9.1 ± 5.3%) than
did explants treated with the control eluate (23.3 ± 19.9%
apoptotic nuclei) (Figs. 6 A, 6B). In explants treated with
10−5 M ouabain, the number of apoptotic nuclei increased
to around 54.3 ± 31.1% (Figs. 6A, 6B). In explants subjected
to retinoschisin and 10−5 M ouabain, 40.3 ± 17.9% apoptotic
nuclei were observed. The difference in the percentages of
apoptotic nuclei between either retinoschisin- or ouabain-
treated explants was statistically significant (P < 0.05).
Digoxin treatment showed similar effects (Fig. 6C,
Supplementary Fig. S4). Although retinoschisin exerted a
protective effect against apoptosis (13.9 ± 16.7% apoptotic
nuclei in retinoschisin treated explants compared with 24.0
± 19.9% in control explants), treatment with 10−6 M digoxin
strongly increased apoptosis (55.4 ± 27.6% apoptotic nuclei;
P < 0.05 compared with retinoschisin-treated explants).
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FIGURE 6. Effect of ouabain and retinoschisin on photoreceptor
degeneration. (A) Retinoschisin-deficient retinae explanted at post-
natal day 18 were cultivated for 4 days in medium containing
retinoschisin (RS1) or control eluate (ctr) in the presence of 0 or
10−5 M ouabain (O), as well as in the presence of 0 or 10−6 M
digoxin (D) (see Supplementary Fig. S4). After washing and embed-
ding, cryosections of the explants were subjected to TUNEL staining
to visualize apoptotic nuclei (green), as well as to DAPI staining to
visualize all nuclei (gray). Scale bars: 25 μm). INL, inner nuclear
layer. (B, C) After TUNEL staining, TUNEL-positive nuclei and all
nuclei were counted in each cryosection with the Cell Counter
plugin for ImageJ, and the percentage of TUNEL-positive nuclei was
calculated. Data represent the mean ± SD of five biological repli-
cates for ouabain treatment (B) and of six biological replicates for
digoxin treatment (C) calibrated against the control. Asterisks repre-
sent statistically significant differences compared with the control
(*P < 0.05; ANOVA test followed by Tukey’s multiple compari-
son test (B) and Kruskall-Wallis test followed by Dunn’s multiple
comparison test and Bonferroni correction (C)).
Explants cultivated in the presence of retinoschisin and
digoxin exhibited 36.4 ± 22.0% apoptotic nuclei.
DISCUSSION
In this study, we investigated the interplay between
retinoschisin and cardiac glycosides at the retinal Na/K-
ATPase, as well as their effect on Na/K-ATPase localization
and retinal integrity. Although cardiac glycosides displaced
retinoschisin from Hek293 cells heterologously expressing
the retinal Na/K-ATPase, from Y-79 cells, and from murine
retinal membranes, retinoschisin did not affect cardiac glyco-
side binding by the retinal Na/K-ATPase. Cardiac glyco-
sides impede retinoschisin-induced enrichment of the retinal
Na/K-ATPase at the inner segments and lessen the protective
effect of retinoschisin against photoreceptor degeneration.
This suggests that a fine-tuned interplay between cardiac
glycosides and retinoschisin is required to maintain retinal
homeostasis.
In this study, cardiac glycosides reduced retinoschisin
binding to the heterologously expressed retinal Na/K-
ATPase. This reduction was not accompanied by a decrease
of retinoschisin in the input or by a decrease of ATP1B2, the
retinoschisin binding partner of the retinal Na/K-ATPase.22
Moreover, cardiac glycosides did not impair retinoschisin
binding to a ouabain-insensitive ATP1A3 mutant, excluding a
Na/K-ATPase-independent interaction between retinoschisin
and cardiac glycosides. Consistent with these in vitro results,
retinoschisin binding to Y-79 cells and murine retinae was
also decreased by cardiac glycosides. Taken together, these
findings suggest a displacement of retinoschisin from the
Na/K-ATPase by cardiac glycosides.
In contrast, cardiac glycoside binding was not affected
by retinoschisin. This raises the question of how the two
components interact at the Na/K-ATPase interface. The bind-
ing site for cardiac glycosides is formed by transmem-
brane helices 1 to 6 of the Na/K-ATPase α subunit,32,35
whereas retinoschisin binds to the extracellular domain of
the β subunit.21 One explanation for the observed effect
of cardiac glycosides on retinoschisin binding could lie
in conformational alterations of the Na/K-ATPase. During
ion transport, the Na/K-ATPase switches between the so-
called E1 (Na+-bound state) and E2 (K+-bound state) confor-
mations.36 This conformational change affects the entire
Na/K-ATPase, including distances between the α and β
subunits.37 Ouabain binding induces the conformational
switch from E1 to E238 and stabilizes the E2 conformation.39
If retinoschisin has a higher affinity for E1, stabilization of
E2 by cardiac glycosides could decrease retinoschisin bind-
ing to the Na/K-ATPase. Alternatively, bound cardiac glyco-
sides could partially overlap with, and potentially block, the
binding region of retinoschisin. Interestingly, the suggested
retinoschisin binding patch on ATP1B2 lies very close to
the outer cardiac glycoside interface of the Na/K-ATPase.
In crystal structure analyses of ATP1A1 and ATP1B1 Na/K-
ATPases, the sugar moieties of bound cardiac glycosides
were located in a cavity enclosed by polar residues of the
α and β subunits (i.e., Gln84 of the ATP1B1-ectodomain).32
The homologous amino acid of Gln84 in ATP1B1 is Glu89
in ATP1B2, which is directly adjacent to the putative
retinoschisin binding patch (composed of four hydrophobic
stretches, amino acids 83–88, 108–121, 181–184, and 240,
on ATP1B2).27 Accessibility to the ATP1B2 binding patch
by retinoschisin might thus be blocked by the protrud-
ing cardiac glycoside sugar moieties. Notably, digoxin has
three sugar moieties and is bulkier than ouabain, which has
only one sugar residue.32 This could explain the stronger
effect of digoxin compared to ouabain on retinoschisin
displacement.
Cardiac glycosides decrease the capacity of retinoschisin
to regulate correct Na/K-ATPase localization at the photore-
ceptor inner segments, likely due to displacement of
retinoschisin at the Na/K-ATPase. Also, cardiac glycosides
and retinoschisin revealed opposing effects on retinal
integrity. Retinoschisin has a known protective effect on
the survival of outer retinal cells,33,34 but the effect of
cardiac glycosides appears to be concentration dependent.
Whereas low levels (10−11 to 10−13 M) of cardiac glycosides
were reported to stimulate retinal explant growth,40 higher
concentrations significantly disrupted retinal integrity and
functionality.41–44 Furthermore, treatment of heart diseases
with cardiac glycosides can have detrimental repercus-
sions on the patients’ vision.10–12 This evidence suggests
that a well-balanced interplay between endogenous cardiac
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glycosides and retinoschisin is crucial for proper photore-
ceptor differentiation and homeostasis.
We have shown that cardiac glycosides displace
retinoschisin from the retinal Na/K-ATPase, affecting the
capacity of retinoschisin to regulate proper Na/K-ATPase
localization and support photoreceptor survival. This obser-
vation suggests opposing roles of cardiac glycosides and
retinoschisin on photoreceptor development and homeosta-
sis and provides an explanation for the pathological side
effects of cardiac glycoside treatment on retinal integrity.
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